2022 vaccine market status and Prospect Analysis
The outbreak of covid-19 (covid-19) since the beginning of 2020 has changed China, the world and everyone's life. Of course, the development of the vaccine industry in the new era of the epidemic has also ushered in new historical opportunities. COVID-19 is testing the global supply chain. As one of the key areas highly dependent on the global supply chain, biopharmaceutical is facing problems such as shortage of pharmaceutical raw materials and insufficient production capacity. The surge in global demand for vaccines in the short term also has an impact on the supply of biological drugs. At present, 10billion doses of vaccine are needed to fully meet the global vaccination needs, and now the effective production capacity is only hundreds of millions. And just the current needs cannot be met.
The International Federation of pharmaceutical manufacturers' associations (IFPMA) predicts that the global vaccine supply and demand will be balanced in June 2022, but Africa may not reach the current vaccine penetration level in North America until 2024. At present, the "covax implementation plan for covid-19 covid-19" launched by who did not meet expectations. By the end of 2021, only 800million doses had been distributed, far lower than the original target of 1.9 billion doses. In 2022, the global vaccine popularization will continue this extremely unbalanced situation. Who also warned that uneven distribution of vaccine would further contribute to the momentum of virus mutation.
With the increasing competition in the vaccine industry, mergers and acquisitions and capital operations among large enterprises are becoming more and more frequent. Excellent vaccine enterprises at home and abroad pay more and more attention to the analysis and research of the industry market, especially the in-depth study of the current market environment and the changes in customer demand trends, in order to occupy the market in advance and obtain the first mover advantage. Because of this, a large number of excellent brands have risen rapidly and gradually become leaders in the industry. The CFAM series cell factory automation equipment of Shenyang GREAT ELITES Intelligent Equipment Co., Ltd. is mainly used in biopharmaceutical cell multiplication culture, which can realize the automatic functions of infusion, liquid level leveling, drainage, cell digestion and vibration in the cell culture process. The equipment is suitable for the production enterprises that produce a large number of vaccines and stem cells.